{"id":564924,"date":"2025-01-02T00:00:00","date_gmt":"2025-01-02T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0051-biopharma-obesity-epidemiology-middle-east-africa\/"},"modified":"2026-03-31T10:27:30","modified_gmt":"2026-03-31T10:27:30","slug":"epidmd0051-biopharma-obesity-epidemiology-middle-east-africa","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidmd0051-biopharma-obesity-epidemiology-middle-east-africa\/","title":{"rendered":"Obesity &#8211; Epidemiology &#8211; Middle East &#038; Africa"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of obesity \/ overweight comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of obesity \/ overweight for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s obesity \/ overweight forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with obesity \/ overweight, how many in each of the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity \/ overweight over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 10 obesity\/overweight patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of obesity \/ overweight.<\/li>\n<li>Undiagnosed prevalent cases of obesity \/ overweight.<\/li>\n<li>Total prevalent cases of obesity.<\/li>\n<li>Total prevalent cases of class I obesity.<\/li>\n<li>Total prevalent cases of class II obesity.<\/li>\n<li>Total prevalent cases of class III obesity.<\/li>\n<li>Total prevalent cases of overweight.<\/li>\n<li>Drug-treatable prevalent cases of overweight.<\/li>\n<li>Diagnosed drug-treated prevalent cases of obesity.<\/li>\n<li>Diagnosed non-drug-treated prevalent cases of obesity.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-564924","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-geography-middle-east-africa","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/564924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/564924\/revisions"}],"predecessor-version":[{"id":575843,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/564924\/revisions\/575843"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=564924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}